Hematology and Oncology Service, Bone Marrow Transplant Program, Hospital Privado Universitario de Cordoba, Instituto Universitario de Ciencias Biomédicas de Cordoba (IUCBC), Cordoba, Argentina.
Department of Clinical Medicine, Hematology and Hemotherapy, University of Sao Paulo (FMUSP), Sao Paulo, Brazil.
JCO Glob Oncol. 2023 May;9:e2200292. doi: 10.1200/GO.22.00292.
Despite strong induction chemotherapy response rates, only 30%-40% of patients with adult B-cell acute lymphoblastic leukemia (ALL) attain long-term remission. This study analyzes ALL in Latin America (LA) and recommends diagnosis, treatment, and management protocols.
The Americas Health Foundation organized a panel of hematologists from Argentina, Brazil, Chile, Colombia, and Mexico to examine ALL diagnosis and therapy and produce recommendations.
Lack of regional data, unequal access to diagnosis and therapy, inadequate treatment response, and uneven health care distribution complicate adult ALL management. The panel recommended diagnosis, first-line and refractory treatment, and post-transplantation maintenance. Targeted treatments, including rituximab, blinatumomab, and inotuzumab ozogamicin, are becoming available in LA and must be equitably accessed.
This review adapts global information on treating ALL to LA. Governments, the medical community, society, academia, industry, and patient advocates must work together to improve policies.
尽管成人 B 细胞急性淋巴细胞白血病（ALL）的诱导化疗缓解率较高，但仅有 30%-40%的患者能获得长期缓解。本研究分析了拉丁美洲（LA）的 ALL，并提出了诊断、治疗和管理建议。
美洲健康基金会组织了来自阿根廷、巴西、智利、哥伦比亚和墨西哥的血液学家小组，以检查 ALL 的诊断和治疗，并提出建议。
缺乏区域数据、诊断和治疗机会不平等、治疗反应不足以及医疗保健分布不均，使得成人 ALL 的管理变得复杂。专家组建议进行诊断、一线和难治性治疗以及移植后维持治疗。在 LA，越来越多的靶向治疗药物（包括利妥昔单抗、blinatumomab 和 inotuzumab ozogamicin）可用于治疗 ALL，必须公平地获得这些药物。
本综述将全球 ALL 治疗信息适用于 LA。政府、医学界、社会、学术界、工业界和患者权益倡导者必须共同努力，改善政策。
